Navigation Links
Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
Date:9/12/2012

BASKING RIDGE, N.J., Sept. 12, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the UBS Global Life Sciences Conference at 2:00 p.m. ET on September 19, 2012 at the Grand Hyatt in New York City.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the groundbreaking results of the REG1 phase 2b trial (RADAR).  Additionally, a summary of the positive results of the FDA end-of-phase 2 meeting and a description of the resulting phase 3 development program and timeline, minimized for cost and maximized for probability of success, will be provided.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3 
Regado's lead program, th
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
2. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
3. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
5. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
9. Thoratec Announces Presentations At Upcoming Investor Conferences
10. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
11. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... WALTHAM, Mass. , March 22 Interleukin Genetics, Inc. (NYSE ... the NYSE Amex LLC (the "Exchange") has granted the Company an extension ... will remain listed up to June 23, 2010 , subject to ... towards the Company,s plan to regain compliance. , ...
... and Manufacturers of America (PhRMA) issued the following statement today on passage of comprehensive health care reform and accompanying reconciliation legislation in the U.S. House of Representatives: , ... , ... ... ...
Cached Medicine Technology:NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 2NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 3PhRMA Statement on Health Care Reform 2PhRMA Statement on Health Care Reform 3PhRMA Statement on Health Care Reform 4PhRMA Statement on Health Care Reform 5
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... MEDmarketplace.com announced today that it has been awarded a ... contracting entity for the Sisters of Mercy Hospital System ... marketplace for selling surplus medical equipment and supplies. ... the agreement, Mercy,s 18 acute care hospitals, two heart ...
... CHICAGO, Dec. 4 The Neurologic & Orthopedic Hospital of,Chicago ... Chicago,Red Stars, a charter member of Women,s Professional Soccer, a ... world. The NOHC will,also be an official partner of ... , Heading the medical ...
... format for its “OneMedForum 2009” finance conference, ... San Francisco at the Sir Francis Drake ... disrupters” affecting each of the following medtech ... and Neurostimulation; Cardiology; Urology and Sexual Health; ...
... Kenneth K. Westbrook, a leading executive in Southern ... Chief Executive Officer of Integrated Healthcare Holdings, Inc., effective ... hospitals in Orange County, California: Western Medical Center -- ... Center and Coastal Communities Hospital. , ...
... blood pressure does not improve a common form of ... international study. , The study, which included researchers ... leadership positions, appears in this week,s issue of the ... , The findings are disappointing to researchers, who continue ...
... programs to help consumers make informed health care decisions , ... While data indicates that area doctors are doing a ... health of their employees, none of this matters if consumers ... to research released today by the Dallas-Fort Worth Business Group ...
Cached Medicine News:Health News:MEDmarketplace.com Signs Contract with Resource Optimization & Innovation (ROi) to Sell Surplus Hospital Equipment 2Health News:MEDmarketplace.com Signs Contract with Resource Optimization & Innovation (ROi) to Sell Surplus Hospital Equipment 3Health News:Neurological & Orthopedic Named Official Hospital of Chicago Red Stars Women's Pro Soccer Team 2Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:Integrated Healthcare Holdings, Inc. Announces New Chief Executive Officer 2Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 2Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 3Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 4
The anti-MAG autoantibodies EIA employs the quantitative enzymatically amplified sandwich-type immunoassay technique. HIGHLY PURIFIED MAG FROM HUMAN BRAIN has been precoated onto a microtiter plate....
... new Enzyme Immuno Assay (EIA) analyzer offering ... a dedicated EVO platform for reliable EIA ... and incubation units operated by the new ... available in three sizes - 100, 150, ...
... trial for 14 years -- and works! ... employs cutting-edge, patent-pending technology to attain the ... unsurpassed accuracy. The technique traces the amount ... blood to determine gender. Here's how it ...
Custom Pediatric Nebulizer Assembly W/Tubing...
Medicine Products: